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assessed after administration of KClO4, an inhibitor of NIS.
Results: The myocardium of transgenic mouse showed intense uptake of 131I (7.1-fold of
control), which was much higher than that of the skeletal muscles, thyroid, and stomach
(figure). Also, the myocardial uptake of 131I was completely blocked by administration of
KClO4.
Conclusion: We developed a transgenic mouse model to image the differentiated cardi-
omyocyte using α-MHC promoter and NIS. The transgenic mouse model is expected to
be effective for tracking cellular differentiation into cardiomyocyte by in vivo imaging
method.
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Background: The αvβ3 integrin is over-expressed in angiogenic vessels, and represents
a potential target for non-invasive imaging of angiogenesis.
Methods: We evaluated a technetium-99m labeled peptide, NC100692 (NC), targeted at
αvβ3 integrin for imaging in an established murine model of angiogenesis induced by
hindlimb ischemia. Mice (n=23) underwent a surgical right femoral artery occlusion (OC)
and contralateral sham operation. NC (1.35±0.15 mCi, i.v.) was injected (INJ) in control
mice or at different times after OC (3d, 7d, 2wk and 8wk), and in vivo pinhole planar
imaging performed at 75 min after INJ. 90 min after NC INJ, tissue from hindlimb (HL)
proximal (P) and distal (D) to OC was excised for gamma well counting (GWC), and for
quantitative immunohistochemical staining of lectin D to OC. HL muscles were divided
into 3 groups for GWC; 1) P upper (U) HL, 2) DUHL, and 3) lower (L) HL. Regional activ-
ity on ischemic (I) HL was normalized to non-ischemic (NI). ROIs were drawn on in vivo
images in region distal to OC, and I/NI ratios calculated.
Results: Relative NC activity by GWC was significantly increased in DUHL and LHL at
7d after OC. On in vivo pinhole images increased focal NC activity was seen distal to OC
at 3d and 7d. Lectin staining confirmed increased angiogenesis in LHL at 3d and 7d post
OC.
Conclusions: NC selectively localized in regions of increased angiogenesis, and was
detectable by non-invasive imaging. NC could potentially be used for non-invasive serial
“hot spot” imaging of angiogenesis.
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Background: Small animal positron emission tomography (microPET) imaging has the
potential to accurately phenotype various rodent models of cardiovascular disease. We
are currently developing and validating techniques to measure myocardial perfusion and
metabolism in rodents that utilize radiotracers and compartmental kinetic models vali-
dated in animal models and applied to humans. We investigated whether differences in
cardiac metabolism could be detected with these techniques.
Methods: Zucker diabetic rats (D) (n=5) and lean controls (L) (n=5) (age:100 ± 27 days)
were studied under fasting conditions in one imaging session. The following measure-
ments were obtained; myocardial blood flow (MBF, mL/g/min) and myocardial oxygen
consumption (MVO2, umol/g/min) with 11C-acetate; myocardial glucose uptake
(MGUp,mL/g/min) and utilization (MGU, nmol/g/min) with 11C-glucose; and fatty acid
uptake (MFAUp mL/g/min), utilization and oxidation (MFAU, MFAO both in nmol/g/min)
with 11C-palmitate.
Results: Heart rate, MBF and MVO2 were not different between L and D. When com-
pared to L, D had higher plasma glucose (16.8 ±3.3 vs 31.6 ±1.8 mmol/L, p<.0001), free
fatty acid (894±519 vs 1665±510 nmol/mL, p<.05) and insulin levels (27±2 vs 61±9 mU/
L, p<.001). Despite higher plasma glucose and insulin levels observed in D, MGUp was
comparable between L and D (0.060±0.034 vs 0.065±0.042); however, due to higher
plasma glucose levels, MGU (MGUp x plasma glucose) tended to be higher in D
(1125±721 vs 2506±1271 p=.1). In contrast, when compared to L, MFAUp (0.38±0.11 vs
0.51±0.04, p<.05), MFAU (306± 126 vs 843±24,p<0.01) and MFAO (230±83 vs 503±205,
p<.05) were higher in D.
Conclusion: The results of this study are consistent with the well-known metabolic
changes that take place in the diabetic heart such as its reliance on fats as source of
energy as well as the observation that derangement of fatty acid metabolism precedes
that of glucose metabolism. This study demonstrates the feasibility of using microPET
imaging to phenotype myocardial metabolism in rodent models of cardiac diseases to
identify biologically relevant models to human disease.
Noon
1116-25 Percutaneous Edge-to-Edge Repair for Mitral 
Regurgitation Guided by Transesophageal and 
Transthoracic Echocardiography
L. Leonardo Rodriguez, Harry Acquatella, Susan Wiegers, Frank Silvestry, Alan 
Zunamon, John Merlino, Randy Martin, Kimberly Krabil, Elyse Foster, Ted Feldman, Jan 
Komtebedde, William J. Stewart, Cleveland Clinic Foundation, Cleveland, OH, Evanston 
Northwestern Healthcare, Evanston, IL
Background: Mitral valve repair is an increasingly attractive alternative to valve replace-
ment, but still requires thoracotomy, cardio-pulmonary bypass, and intraoperative
echocardiographic monitoring. Successful valve repairs using the edge-to-edge surgical
technique (Alfieri) have been reported. This paper presents the initial experience with
echocardiography in performing the percutaneous endovascular repair.
Methods: The endovascular Mitral Repair System (EvalveTM Redwood City, CA) uses a
steerable guide catheter to position a two-armed, V-shaped device, to approximate the
leaflet tissue near the midline of the valve. The delivery of Evalve has 5 essential steps
that require echo guidance: 1-transseptal crossing, 2-alignment of the delivery system
perfectly perpendicular to the mitral valve plane and in the center of the coaptation line 3-
alignment of the approximation implant device with the open arms perpendicular to the
coaptation line, 4- closing of the arms and approximation of the tips of the mitral valve
and 5- release of the implant device.
Results: We used a combination of transesophageal echo (TEE) and transthoracic echo
(TTE) to guide the entire procedure in 5 cases, the first performed in humans. TEE was
instrumental during steps 1, 2, 4 and 5 and TTE was helpful in step 2 and essential in
step 3. At the end of the procedure it was possible to image the 'figure 8" diastolic shape
of the double mitral valve orifice. Echo also allowed monitoring of the degree of mitral
regurgitation (MR) and transmitral gradients before and immediately after the procedure.
MR was significantly reduced in all 5 cases.
Conclusions: 1) Echocardiography, using a combination of surface and transthoracic
echo, is an essential tool for guiding the Evalve endovascular repair. 2) Endovascular
mitral valve repair appears feasible in human with severe mitral regurgitation.
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Backgrounds. To offer a therapeutic option to end-stage non-operable patients (Pts)
with calcific aortic stenosis (AS), we developed a percutaneous heart valve (PHV) made
of three-leaflets equine pericardium mounted in a stainless steel balloon expandable
stent.
Methods. The PHV is crimped on a 22 mm diameter-balloon catheter advanced over a
0.035 extra-stiff guidewire through a 24 Fr introducer, and delivered by balloon inflation.
This PHV was extensively tested in-vitro and in animals before being implanted in 6 Pts
(5 male; 75 + 12 yrs. Results. All Pts had severe calcific AS (0.5 + 0.1 cm²), were in
NYHA class IV and were declined for surgery due to cardiac (cardiogenic shock in two,
low ejection fraction, previous bypass surgery, porcelain aorta) and/or extracardiac rea-
sons (subacute leg ischemia; previous or evolving cancer; renal failure; stroke; age > 90
yrs). Under local anesthesia and mild sedation, the antegrade trans-septal route was
used for PHV implantation. After pre-dilatation of the native valve, PHV was successfully
deployed at mid-native aortic valve in all except one (immediate migration of PHV in the
ascending aorta leading to death in a Pt with cardiogenic shock). Autopsy revealed an
arrachement of the leaflet related to pre-dilatation. Valvular function was dramatically
improved with an increase in valve area to 1.7 + .03 cm2. Supra-aortic angiogram
showed patent coronary ostia, and mild (3 Pts) or severe (2 Pts) paravalvular aortic
regurgitation. PHV implantation led to early hemodynamic and clinical improvements. At
one week, EF was increased from 24+9 to 41+12%. Valvular function was unchanged
during follow-up on sequential echographic assessment. Three Pts died of non cardiac
cause: complication of mid-thigh amputation at 4 mths, acute abdominal syndrome at 3
weeks, hemorrhage from rectal carcinoma at 2 weeks. The two last Pts are alive.
Conclusions. This early experience confirmed that PHV implantation is feasible, leading
to dramatic valvular function improvement. Prospective studies are ongoing in our center
(I-REVIVE) and in the US and will further determine the place of this promising new ther-
apeutic alternative in non operable patients with calcific AS.
* p<0.05 vs control
NC Activity  (I/NI) Controln = 5
3 days
n = 5
7 days
n = 4
2 wks
n = 4
8 wks
n = 5
GWC PUHL 1.03±0.07 1.06±0.12 0.95±0.30 1.10±0.44 0.97±0.06
GWC DUHL 0.91±0.07 1.07±0.25 1.27±0.17* 1.19±0.38 1.04±0.13
GWC LHL 0.95±0.04 2.06±1.22 3.58±0.21* 1.47±0.57 1.10±0.18
Image LHL 0.82±0.1 1.13±0.2* 1.4±0.15* 1.18±0.25 0.9±0.15
